Nighan Warren JR

SEC source: 0001140361-26-030514 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,745

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.65 to $14.80, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001140361-26-029635 · form4.xml · derivative · entry 3

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,052 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 19, 2023, the reporting person received a target grant of 20,052 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2024, 2025 and 2026 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,694 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-26-029635 · form4.xml · nonDerivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,115

F2 · shares: The exempt disposition of 1,671 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029635 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,786

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 5,694 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-26-029181 · form4.xml · nonDerivative · entry 3

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,126

F3 · shares: The exempt disposition of 251 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-26-029181 · form4.xml · nonDerivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 66,377

F2 · shares: The exempt disposition of 1,373 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2024.

SEC source: 0001140361-26-029181 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,750

F1 · shares: The exempt disposition of 2,153 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 16, 2025.

SEC source: 0001140361-26-029332 · form4.xml · derivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 17,966

Underlying: Common Stock · 17,966 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-26-029332 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 84,092

F1 · shares: The acquisition of 17,966 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 17,966 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 15, 2027, such that 25% of the restricted stock units will vest on each of July 15, 2027, 2028, 2029 and 2030.

SEC source: 0001140361-25-026798 · form4.xml · nonDerivative · entry 3

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 69,903

F3 · shares: The exempt disposition of 277 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-25-026798 · form4.xml · nonDerivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,180

F2 · shares: The exempt disposition of 251 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-25-026798 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,431

F1 · shares: The exempt disposition of 735 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-25-026465 · form4.xml · derivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 29,349

Underlying: Common Stock · 29,349 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-25-026465 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 71,166

F1 · shares: The acquisition of 29,349 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 29,349 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 16, 2026, such that 25% of the restricted stock units will vest on each of July 16, 2026, 2027, 2028 and 2029.

SEC source: 0001140361-25-001388 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,817

SEC source: 0001140361-24-043263 · form4.xml · nonDerivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,877

SEC source: 0001140361-24-043263 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,777

SEC source: 0001140361-24-034269 · form4.xml · nonDerivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 40,998

F2 · shares: The exempt disposition of 277 shares of common stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares of underlying restricted stock units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-24-034269 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,275

F1 · shares: The exempt disposition of 251 shares of common stock of AngioDynamics, Inc. ("AngioDynamics") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 20, 2022.

SEC source: 0001140361-24-033785 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,526

F1 · shares: The exempt disposition of 735 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 19, 2023.

SEC source: 0001140361-24-033634 · form4.xml · derivative · entry 3

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,507

Underlying: Common Stock · 23,507 shares

Expires 2034-07-17

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2025, such that 25% of the options will vest on each of July 17, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-24-033634 · form4.xml · derivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,952

Underlying: Common Stock · 23,952 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-24-033634 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,261

F1 · shares: The acquisition of 18,733 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 18,733 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 17, 2025, such that 25% of the restricted stock units will vest on each of July 17, 2025, 2026, 2027 and 2028.

SEC source: 0001140361-24-035599 · form4.xml · derivative · entry 3

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 7,550 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On July 21, 2021, the reporting person received a target grant of 7,550 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,677 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On July 21, 2021, the reporting person received a target grant of 7,550 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,677 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On July 21, 2021, the reporting person received a target grant of 7,550 performance share units. Between 0% and 200% of the target number was to be earned based on achievement of pre-determined performance metrics for fiscal years 2022, 2023 and 2024 as determined by the compensation committee. In addition, 20% of the total shares earned could be awarded (or cancelled) based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics. Based on performance over the period, 5,677 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001140361-24-035599 · form4.xml · nonDerivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 45,009

F2 · shares: The exempt disposition of 1,666 shares of Common Stock of AngioDynamics was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 21, 2021.

SEC source: 0001140361-24-035599 · form4.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,675

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 5,677 shares of Common Stock ("Common Stock") of AngioDynamics, Inc. ("AngioDynamics") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 21, 2021.

SEC source: 0001567619-22-014375 · doc1.xml · derivative · entry 3

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,027

Underlying: Common Stock · 8,027 shares

Expires 2032-07-20

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 20, 2023, such that 25% of the options will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-014375 · doc1.xml · derivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,852

Underlying: Common Stock · 6,852 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-22-014375 · doc1.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,619

F1 · shares: The acquisition of 3,426 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 3,426 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 20, 2023, such that 25% of the restricted stock units will vest on each of July 20, 2023, 2024, 2025 and 2026.

SEC source: 0001567619-22-013846 · doc1.xml · derivative · entry 3

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 6,452 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 6,452 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,233 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 6,452 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,233 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 6,452 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 3,233 shares of Common Stock were issued to the reporting person under this grant and the remaining shares were forfeited.

SEC source: 0001567619-22-013846 · doc1.xml · nonDerivative · entry 2

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,193

F2 · shares: The exempt disposition of 919 shares of Common Stock to the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-22-013846 · doc1.xml · nonDerivative · entry 1

Nighan Warren JR · CIK 0001507345 · SVP Quality and Regulatory

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,112

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 3,233 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.